Therapeutics
- Ref-No. Technology
-
01-01036
Novel therapy approach for treatment of lung fibrosis
-
01-01080
Drug combinations to overcome therapy resistance in cancer
-
01-01085
Expansion of pancreatic progenitors derived from human pluripotent stem cells und GMP-compliant conditions
-
02-00311
Cystobactamids – novel antibacterials against gram-negative pathogens
-
02-00337
Novel Labyrinthopeptins as anti-viral agents
-
02-00351
Increased Availability and Efficacy of Aminoglycosides
-
02-00354
Highly active Chlorotonil A Derivatives for the treatment of Malaria
-
02-00369
Biodynamers enhance drug delivery
-
02-00372
Oral Antimotilin-Based Inhibitors for Treating Helicobacter pylori Infections
-
02-00373
First-in-Class S. aureus α-Hemolysin Inhibitors for Lung and Skin Infections
-
02-00376
Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
-
02-00378
Best-In-Class P. aeruginosa LasB virulence factor Inhibitors
-
02-00385
Next-Generation Probiotics
-
02-00387
Best-in-class Darobactin derivate against Gram-negative Bacteria
-
02-00396
Novel Lectin-Targeting therapeutics and diagnostics for Pseudomonas aeruginosa infections
-
02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
-
02-00402
Novel inhibitors of Cytomegalovirus
-
02-00404
Inhibitors of Energy Coupling Factor (ECF) Transporters Against Gram-Positive Pathogens
-
02-00415
Thiourea-Based Antibiotics against Acinetobacter baumannii
-
02-00423
DeColi: Gut Decolonization of Multi-Resistant Escherichia coli
-
02-00432
Novel ASO-Based mRNA Silencing Technology for Phage-Host Interaction Research
-
03-00251
Stable Gene Transfer with Hyperactive Sleeping Beauty Transposase SB100X
- 03-00367 Targeting of Autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer’s and vascular dementia
-
03-00393
Novel TPH inhibitors for the treatment of fibrotic diseases and pulmonary arterial hypertension (PAH)
-
03-00397
Plasma cell-specific antibodies targeting BCMA for the treatment of multiple myeloma and autoimmune diseases
-
03-00413
Improved Sleeping Beauty Transposon System for gene therapy: SB100X/pT4
-
03-00430
Selective Inhibitors of Genotoxic Stress Induced IKK/NFκB Pathways for Cancer Therapy
-
03-00481
Spacer-nick genome editing of hematopoietic stem and progenitor cells and T cells
-
03-00553
Human TCR constructs for adoptive cell therapy of cancer
-
10-00087
Jagaricin – a novel antifungal natural compound
-
10-00128
Functionalized Nanoparticles for Viral Clearance
-
11-00065
Nutritional compositions for treating dysfunction of liver fat metabolism – VAFD
-
11-00068
Dream Complex Inhibitors for Treating Medical Conditions Induced by Circadian Rhythm Disruption
- 15-00436 MicroRNA-125b-5p – a new treatment option for drug induced Acute Liver Failure
-
15-00446
Liver stem cell generation for therapeutic applications
-
15-00461a
The physiological breast-milk proteins S100A8 and S100A9 promote an eubiotic gut state in infants
-
15-00461b
Novel treatment for sepsis in newborns
-
15-00514
LS-COAT – an exceptionally efficient tumor vaccination approach
-
15-00611
Engineered Immune Cells to Specifically Eliminate Undesired Immune Responses
- 15-00612 TCR-agnostic identification of tumor-specific T cells for cancer diagnostics and therapy
-
15-00648
AAV Vector Variants for Ocular Gene Delivery
-
15-00651
Novel Treatment of Pulmonary Arterial Hypertension (PAH)
-
15-00694
HLA-DR-specific γδ T-cell receptor to treat proliferative disorders of HLA-DR+ cells
-
21-00019
Microelectrode array with combined optical stimulation
-
21-00027
Ferulic acid derivatives as efficient neuroprotective agent and memory enhancer
-
21-00035
Novel Therapy for Treatment of Alzheimer´s Disease
- 22-00009 Quiescent B Cells for immune suppression in gene therapy
- 22-00017 Functional IFN-gamma memory in CD4+ T cells: Method for improved T cell therapy and disease monitoring in autoimmune diseases
- 22-00020 Bispecific antibodies for cell-type-specific TNF inhibition
-
23-00046
microRNA Signature Indicates Risk for Cognitive Decline
-
23-00064
Treating dementia and other brain disorders with natural glycans
- 23-00065 Novel treatment of dementia-associated tauopathies
-
23-00069
NMDAR targeted CAAR-T cell therapy
-
23-00075
HERV inhibitors for use in tauopathies
-
32-00059
T-cell therapy of MYD88L265P-dependent B-cell lymphoma
-
32-00076
Next generation allogeneic CAR-NK cell platform for treatment of malignant diseases
-
32-00082
Reprogramming immune cells for CAR cell-based therapies
-
32-00083
Immunosuppressant resistance in anti-viral T cell products
-
32-00099
A novel immuno-oncology approach for induction and massive amplification of antigen-specific cytotoxic CD8+ T-cells
-
32-00101
High-level recombinant adeno-associated virus production
-
32-00164
The CXCR3alt-CXCL11 chemokine system for therapeutic use in solid cancer
-
32-00192
Base editing enzymes for multiplex editing with simultaneous gene knock-in and knock-out
-
32-00222
Method for direct measurement of functional avidity of T cells
-
42-00047
Tyrolian algae extract with anti-inflammatory potential
-
42-00076
NICHE-CAR-T: NR2F6 Immune Checkpoint Harnessing to Enhance CAR-T efficacy
-
44-00013
Keratinophile photosensitizers for safe and rapid treatment of onychomycosis
